Stephen Forman, MD
Leading Expert in Bone Marrow Transplantation, Treatment of Hematologic Malignancies and the Chimeric Antigen Receptor (CAR) T Cell-Based Immunotherapeutics
Chair and Professor of Hematology, City of Hope
Professor of Surgery, Imperial College London
Marcin Kortylewski, PhD
Cancer scientist who co-discovered the key role of STAT3 as an inhibitor of immune activity in the tumor microenvironment. He is also an inventor of targeted, bi-functional CpG-STAT3 inhibitors for cancer immunotherapy. Dr. Kortylewski is an Associate Professor of Immuno-Oncology at City of Hope National Medical Center.
John Rossi, PhD
World-Leader in the development and clinical application of oligonucleotide therapeutics, co-Founder of Dicerna Pharmaceuticals, Calando Pharmaceuticals, and MiNA Therapeutics.
Dr. Rossi is a Professor at City of Hope National Medical Center, and the Chair of its Department of Molecular and Cellular Biology.
Paloma Giangrande, PhD
Professor, University of Iowa
Director, Moderna Therapeutics
Oligonucleotide therapeutics expert
Sumanta Pal, MD
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope
Nagy Habib, MD
Clinical Scientist, Inventor and Entrepreneur. Co-Founder of MiNA Therapeutics
Medical oncologist and clinical scientist